-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Matinas BioPharma (NYSEAMERICAN:MTNB) Releases Quarterly Earnings Results, Meets Estimates
Matinas BioPharma (NYSEAMERICAN:MTNB) Releases Quarterly Earnings Results, Meets Estimates
Matinas BioPharma (NYSEAMERICAN:MTNB – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03), Fidelity Earnings reports.
Matinas BioPharma Trading Down 0.6 %
NYSEAMERICAN MTNB traded down $0.00 during trading hours on Friday, reaching $0.84. The company's stock had a trading volume of 1,632 shares, compared to its average volume of 353,303. Matinas BioPharma has a 1 year low of $0.49 and a 1 year high of $1.61. The stock has a market cap of $182.60 million, a PE ratio of -7.66 and a beta of 1.96.
Get Matinas BioPharma alerts:Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Atria Wealth Solutions Inc. purchased a new position in Matinas BioPharma in the 1st quarter worth approximately $32,000. Private Advisor Group LLC increased its stake in Matinas BioPharma by 59.7% in the 1st quarter. Private Advisor Group LLC now owns 239,494 shares of the company's stock worth $192,000 after acquiring an additional 89,553 shares during the last quarter. State Street Corp increased its stake in Matinas BioPharma by 8.0% in the 1st quarter. State Street Corp now owns 712,471 shares of the company's stock worth $573,000 after acquiring an additional 52,897 shares during the last quarter. Finally, BlackRock Inc. increased its stake in Matinas BioPharma by 0.7% in the 1st quarter. BlackRock Inc. now owns 4,325,053 shares of the company's stock worth $3,479,000 after acquiring an additional 29,643 shares during the last quarter. 12.40% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, Aegis reiterated a "buy" rating on shares of Matinas BioPharma in a report on Thursday, June 23rd.About Matinas BioPharma
(Get Rating)
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Featured Articles
- Get a free copy of the StockNews.com research report on Matinas BioPharma (MTNB)
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
Matinas BioPharma (NYSEAMERICAN:MTNB – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03), Fidelity Earnings reports.
Matinas BioPharma(NYSEAMERICAN:MTNB-GET Rating)周四发布了季度收益报告。富达收益报告显示,该公司本季度每股收益为0.03美元,符合市场普遍预期的0.03美元。
Matinas BioPharma Trading Down 0.6 %
Matinas BioPharma股价下跌0.6%
NYSEAMERICAN MTNB traded down $0.00 during trading hours on Friday, reaching $0.84. The company's stock had a trading volume of 1,632 shares, compared to its average volume of 353,303. Matinas BioPharma has a 1 year low of $0.49 and a 1 year high of $1.61. The stock has a market cap of $182.60 million, a PE ratio of -7.66 and a beta of 1.96.
NYSEAMERICAN MTNB在周五的交易时段下跌了0.00美元,达到0.84美元。该公司股票的成交量为1,632股,而其平均成交量为353,303股。Matinas BioPharma的一年低点为0.49美元,一年高位为1.61美元。该股市值为1.826亿美元,市盈率为-7.66,贝塔系数为1.96。
Institutional Inflows and Outflows
机构资金流入和流出
Large investors have recently added to or reduced their stakes in the business. Atria Wealth Solutions Inc. purchased a new position in Matinas BioPharma in the 1st quarter worth approximately $32,000. Private Advisor Group LLC increased its stake in Matinas BioPharma by 59.7% in the 1st quarter. Private Advisor Group LLC now owns 239,494 shares of the company's stock worth $192,000 after acquiring an additional 89,553 shares during the last quarter. State Street Corp increased its stake in Matinas BioPharma by 8.0% in the 1st quarter. State Street Corp now owns 712,471 shares of the company's stock worth $573,000 after acquiring an additional 52,897 shares during the last quarter. Finally, BlackRock Inc. increased its stake in Matinas BioPharma by 0.7% in the 1st quarter. BlackRock Inc. now owns 4,325,053 shares of the company's stock worth $3,479,000 after acquiring an additional 29,643 shares during the last quarter. 12.40% of the stock is owned by hedge funds and other institutional investors.
大型投资者最近增持或减持了该公司的股份。Atria Wealth Solutions Inc.在第一季度购买了Matinas BioPharma的一个新头寸,价值约3.2万美元。Private Advisor Group LLC在第一季度增持了Matinas BioPharma 59.7%的股份。Private Advisor Group LLC在上个季度增持了89,553股后,现在拥有239,494股该公司股票,价值192,000美元。道富集团第一季度增持Matinas BioPharma 8.0%的股份。道富银行目前持有该公司712,471股股票,价值573,000美元,此前该公司在上个季度增持了52,897股股票。最后,贝莱德股份有限公司在第一季度增持了马蒂纳斯生物制药0.7%的股份。贝莱德股份有限公司在上个季度增持了29,643股后,目前持有该公司4,325,053股股票,价值3,479,000美元。12.40%的股票由对冲基金和其他机构投资者持有。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
About Matinas BioPharma
关于Matinas BioPharma
(Get Rating)
(获取评级)
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Matinas BioPharma Holdings,Inc.是一家临床阶段的生物制药公司,专注于发现和开发各种候选产品。它利用其脂质纳米晶体(LNC)平台技术开发产品。该公司的LNC输送技术平台利用脂质纳米晶体输送小分子、核酸、基因疗法、疫苗、蛋白质和多肽。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Matinas BioPharma (MTNB)
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- 免费获取StockNews.com关于Matinas BioPharma(MTNB)的研究报告
- 机构和分析师推动Jack in the Box走高
- 你能猜到哪个电动车股票打败了特斯拉吗?
- 霍尼韦尔看好稳定和多元化的股票
- 为什么要投资高收益股利股票?
- 迪士尼(NYSE:DIS)的股票刚刚给了投资者一个巨大的信号
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
获得Matinas BioPharma Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Matinas BioPharma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧